A
19.98
-0.20 (-0.99%)
| Previous Close | 20.18 |
| Open | 19.92 |
| Volume | 551,831 |
| Avg. Volume (3M) | 1,050,404 |
| Market Cap | 2,483,813,632 |
| Price / Earnings (Forward) | 111.11 |
| Price / Sales | 656.60 |
| Price / Book | 13.06 |
| 52 Weeks Range | |
| Earnings Date | 27 Nov 2024 - 2 Dec 2024 |
| Operating Margin (TTM) | -2,785.05% |
| Diluted EPS (TTM) | -5.00 |
| Total Debt/Equity (MRQ) | 133.97% |
| Current Ratio (MRQ) | 4.65 |
| Operating Cash Flow (TTM) | -351.56 M |
| Levered Free Cash Flow (TTM) | -413.91 M |
| Return on Assets (TTM) | -40.72% |
| Return on Equity (TTM) | -151.84% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Arrowhead Pharmaceuticals, Inc. | Bearish | Bullish |
AIStockmoo Score
0.3
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | 0.25 |
|
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 4.47% |
| % Held by Institutions | 79.71% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 80.00 (HC Wainwright & Co., 300.40%) | Buy |
| Median | 43.50 (117.72%) | |
| Low | 24.00 (Bernstein, 20.12%) | Hold |
| Average | 46.17 (131.08%) | |
| Total | 4 Buy, 2 Hold | |
| Avg. Price @ Call | 23.26 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 20 Dec 2024 | 80.00 (300.40%) | Buy | 19.45 |
| 03 Dec 2024 | 80.00 (300.40%) | Buy | 26.07 | |
| Chardan Capital | 12 Dec 2024 | 60.00 (200.30%) | Buy | 22.14 |
| 27 Nov 2024 | 60.00 (200.30%) | Buy | 26.15 | |
| Bernstein | 29 Nov 2024 | 24.00 (20.12%) | Hold | 26.03 |
| Citigroup | 27 Nov 2024 | 26.00 (30.13%) | Hold | 26.15 |
| Piper Sandler | 27 Nov 2024 | 45.00 (125.23%) | Buy | 26.15 |
| 08 Oct 2024 | 62.00 (210.31%) | Buy | 18.02 | |
| RBC Capital | 26 Sep 2024 | 42.00 (110.21%) | Buy | 19.62 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |